Antimicrobial assay optimization and validation for HTS in 384-well format using a bioluminescent E. coli K-12 strain

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 782-789

  Nybond, Susanna ^a   Karp, Matti ^b   Tammela, Päivi ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Bioluminescence; Cell based assay; High throughput screening; Miniaturization; Transcription; Translation

Indexed keywords

ERYTHROMYCIN; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ASSAY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BIOLUMINESCENCE; CONCENTRATION RESPONSE; DNA SYNTHESIS; ESCHERICHIA COLI K 12; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; ROBOTICS;

EID: 84880184614     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.05.024     Document Type: Article

References (31)

1. An, W.F., Tolliday, N., 2010. Cell-based assays for high-throughput screening. Mol. Biotechnol. 45, 180-186.
2. Bollini, S., Herbst, J.J., Gaughan, G.T., Verdoorn, T.A., Ditta, J., Dubowchik, G.M., Vinitsky, A., 2002. High-throughput fluorescence polarization method for identification of FKBP12 ligands. J. Biomol. Screen. 7, 526-530. (Pubitemid 135752867)
3. Butler, M.S., Cooper, M.A., 2011. Antibiotics in the clinical pipeline in 2011. J. Antibiot. (Tokyo) 64, 413-425.
4. Coates, A.R.M., Halls, G., 2012. Antibiotics in phase II and III clinical trials. Handb. Exp. Pharmacol. 211, 167-183.
5. Cummings, D.J., 2006. Pharmaceutical drug discovery: designing the blockbuster drug. In: Dean, A.M., Lewis, S. (Eds.), Screening: Methods for Experimentation in Industry, Drug Discovery, and Genetics. Springer Science + Business Media Inc., New York, USA, pp. 69-75.
6. Elsea, S.H., Westergaard, M., Burden, D.A., Lomenick, J.P., Osheroff, N., 1997. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry 36, 2919-2924. (Pubitemid 27138575)
7. French, G.L., 2010. The continuing crisis in antibiotic resistance. Int. J. Antimicrob. Agents 36 (Suppl. 3), S3-S7.
8. Galluzzi, L., Karp, M., 2003. Amplified detection of transcriptional and translational inhibitors in bioluminescent Escherichia coli K-12. J. Biomol. Screen. 8, 340-346.
9. Galluzzi, L., Karp, M., 2006. Whole cell strategies based on lux genes for high throughput applications toward new antimicrobials. Comb. Chem. High Throughput Screen. 9, 501-514. (Pubitemid 44156708)
10. Gwynn, M.N., Portnoy, A., Rittenhouse, S.F., Payne, D.J., 2010. Challenges of antibacterial discovery revisited. Ann. N. Y. Acad. Sci. 1213, 5-19.
11. Hogberg, L.D., Heddini, A., Cars, O., 2010. The global need for effective antibiotics: challenges and recent advances. Trends Pharmacol. Sci. 31, 509-515.
12. Iversen, P.W., Beck, B., Chen, Y.F., Dere, W., Devanarayan, V., Eastwood, B.J., Farmen, M.W., Iturria, S.J., Montrose, C., Moore, R.A., Weidner, J.R., Sittampalam, G.S., 2004. HTS assay validation. In: Sittampalam, G.S., Gal-Edd, N., Arkin, M., Auld, D., Austin, C., Bejcek, B., Glicksman, M., Inglese, J., Lemmon, V., Li, Z., McGee, J., McManus, O., Minor, L., Napper, A., Riss, T., Trask, O.J., Weidner, J. (Eds.), Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD).
13. Korpela, M.T., Kurittu, J.S., Karvinen, J.T., Karp, M.T., 1998. A recombinant Escherichia coli sensor strain for the detection of tetracyclines. Anal. Chem. 70, 4457-4462.
14. Kruszewska, H., Zareba, T., Tyski, S., 2006. Estimation of antimicrobial activity of selected non-antibiotic products. Acta Pol. Pharm. 63, 457-460.
15. Leung, E., Weil, D.E., Raviglione, M., Nakatani, H., World Health Organization World Health Day Antimicrobial Resistance Technical Working Group, 2011. The WHO policy package to combat antimicrobial resistance. Bull. World Health Organ. 89, 390-392.
16. Macarron, R., Hertzberg, R.P., 2011. Design and implementation of high throughput screening assays. Mol. Biotechnol. 47, 270-285.
17. Meighen, E.A., 1991. Molecular biology of bacterial bioluminescence. Microbiol. Rev. 55, 123-142. (Pubitemid 21895148)
18. Michelini, E., Cevenini, L., Mezzanotte, L., Coppa, A., Roda, A., 2010. Cell-based assays: fuelling drug discovery. Anal. Bioanal Chem. 398, 227-238.
19. Monaghan, R.L., Barrett, J.F., 2006. Antibacterial drug discovery-then, now and the genomics future. Biochem. Pharmacol. 71, 901-909.
20. Norrby, S.R., Nord, C.E., Finch, R., European Society of Clinical Microbiology and Infectious Diseases, 2005. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115-119. (Pubitemid 40174782)
21. O'Neill, A.J., 2008. New antibacterial agents for treating infections caused by multidrug resistant Gram-negative bacteria. Expert Opin. Investig. Drugs 17, 297-302. (Pubitemid 351578182)
22. Roda, A., Guardigli, M., Pasini, P., Mirasoli, M., 2003. Bioluminescence and chemiluminescence in drug screening. Anal. Bioanal Chem. 377, 826-833. (Pubitemid 40877848)
23. Russell, A.D., 1991. Mechanisms of bacterial resistance to non-antibiotics: food additives and food and pharmaceutical preservatives. J. Appl. Bacteriol. 71, 191-201.
24. Sarker, S.D., Nahar, L., Kumarasamy, Y., 2007. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals. Methods 42, 321-324. (Pubitemid 46856865)
25. Scott, D., Dikici, E., Ensor, M., Daunert, S., 2011. Bioluminescence and its impact on bioanalysis. Annu. Rev. Anal. Chem. 4, 297-319.
26. Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H.W., Scheld, W.M., Bartlett, J.G., Edwards Jr., J., Infectious Diseases Society of America, 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164. (Pubitemid 351269151)
27. Tenhami, M., Hakkila, K., Karp, M., 2001. Measurement of the effects of antibiotics in bioluminescent Staphylococcus aureus RN4220. Antimicrob. Agents Chemother. 45, 3456-3461. (Pubitemid 33107862)
28. Theuretzbacher, U., 2012. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int. J. Antimicrob. Agents 39, 295-299.
29. Xu, H.X., Lee, S.F., 2004. The antibacterial principle of Caesalpina sappan. Phytother. Res. 18, 647-651. (Pubitemid 39329715)
30. Zhang, J.H., Chung, T.D., Oldenburg, K.R., 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73. (Pubitemid 29278954)
31. Zhong, X., Wu, B., Pan, Y.J., Zheng, S., 2009. Brazilein inhibits survivin protein and mRNA expression and induces apoptosis in hepatocellular carcinoma HepG2 cells. Neoplasma 56, 387-392.